Most nanoparticle-based cancer therapeutic strategies seek to develop an effective individual cancer cell or metastatic tumor treatment. Critical to the success of these therapies is to direct as much of the agent as possible to the targeted tissue while avoiding unacceptable normal tissue complications. In this light, three different cisplatinum/magnetic nanoparticle (mNP) administration regimens were investigated. The most important finding suggests that clinically relevant doses of cisplatinum result in a significant increase in the tumor uptake of systemically delivered mNP. This enhancement of mNP tumor uptake creates the potential for an even greater therapeutic ratio through the addition of mNP based, intracellular hyperthermia.

Date Published: 26 February 2013
PDF: 7 pages
Proc. SPIE 8584, Energy-based Treatment of Tissue and Assessment VII, 85840H (26 February 2013); doi: 10.1117/12.2007308

Published in SPIE Proceedings Vol. 8584:
Energy-based Treatment of Tissue and Assessment VII
Thomas P. Ryan, Editor(s)